EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer
Combining the Nectin-4 antibody-drug conjugate enfortumab vedotin with pembrolizumab nearly doubled survival compared with platinum chemotherapy in advanced urothelial cancer, the biggest advance in this disease in 40 years.
Open-label phase 3 trial of 886 patients with untreated locally advanced or metastatic urothelial carcinoma, eligible for cisplatin or carboplatin, randomised to enfortumab vedotin plus pembrolizumab or gemcitabine plus platinum. Dual primary endpoints were PFS by blinded review and OS.
Median PFS was 12.5 vs 6.3 months (HR 0.45) and median OS 31.5 vs 16.1 months (HR 0.47), with benefit regardless of cisplatin eligibility or PD-L1 expression. It displaced platinum chemotherapy as first-line standard of care, the first regimen to do so since the 1980s, and is the first ADC plus checkpoint inhibitor combination to become a first-line standard in any cancer.
- Median PFS 12.5 vs 6.3 months; HR 0.45 (95% CI 0.38-0.54).
- Median overall survival 31.5 vs 16.1 months; HR 0.47 (95% CI 0.38-0.58).
- Objective response 67.7% vs 44.4%; complete response 29.1% vs 12.5%.
- Benefit consistent in cisplatin-eligible and -ineligible patients and in PD-L1 high and low tumours.
- Grade 3 or higher treatment-related adverse events 55.9% vs 69.5%; skin reactions, peripheral neuropathy and hyperglycaemia were the characteristic toxicities of enfortumab vedotin.
Almost every patient newly diagnosed with advanced bladder or urothelial cancer should now be offered enfortumab vedotin plus pembrolizumab rather than chemotherapy, with median survival extended from about 16 months to over two and a half years. Neuropathy and skin toxicity need monitoring and dose adjustment, and patients with severe diabetes or pre-existing neuropathy need care. Platinum chemotherapy remains an option for those who cannot receive the combination.
- Open-label; PFS by blinded review.
- Only about 30% of chemotherapy patients received maintenance avelumab, which is standard, so the control arm may have underperformed.
- Peripheral neuropathy is cumulative and often persistent, affecting quality of life in long survivors.
- Very high cost; access outside high-income countries is limited.
Pages like this
not linked directly; found by shared links- Key paperCLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer
Shares Lines of therapy, Objective response rate (ORR), Merck & Co. (MSD), Too many combinations to test.
- Key paperKEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer
Shares Standard of care, Merck & Co. (MSD), Overall survival (OS), Progression-free survival (PFS).
- Key paperKEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer
Shares Lines of therapy, Objective response rate (ORR), Merck & Co. (MSD), Overall survival (OS).
- Key paperKEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation
Shares Lines of therapy, Merck & Co. (MSD), Overall survival (OS), Progression-free survival (PFS).
- Key paperRELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma
Shares Lines of therapy, Too many combinations to test, Overall survival (OS), Progression-free survival (PFS).
- PairingADC + checkpoint inhibitor
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
- Key paperHARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer
Shares Lines of therapy, Merck & Co. (MSD), Overall survival (OS), Progression-free survival (PFS).
- PairingEnfortumab vedotin + pembrolizumab across the bladder cancer continuum
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.